Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Journal of Liposome Research|December 29, 2025
Pyrophosphate-modified liposomes for bone-targeted deliveryAlberto Dal Corso, Riccardo Becchetti, Cristina Matteo, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2009
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequencesAmalia Azzariti, Letizia Porcelli, Grazia M Simone, et al.
Neoplasia (New York, N.Y.)|April 2, 2018
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma CellsLuca Mologni, Mariantonia Costanza, Geeta Geeta Sharma, et al.
Pediatric Blood & Cancer|May 13, 2022
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase productCristina Matteo, Antonella Colombini, Laura Rachele Bettini, et al.
Biochemical Pharmacology|September 6, 2005
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecanAngela Maria Di Francesco, Anna Riccardi, Anna Shirley Riccardi, et al.
Molecular Cancer Therapeutics|December 29, 2012
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenograftsEzia Bello, Giulia Taraboletti, Gennaro Colella, et al.
Therapeutic Drug Monitoring|February 6, 2020
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 StudyGudrun Würthwein, Claudia Lanvers-Kaminsky, Joachim Gerss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patientsCarlo Gambacorti-Passerini, Massimo Zucchetti, Domenico Russo, et al.
Neoplasia (New York, N.Y.)|December 19, 2016
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer ModelsFederica Guffanti, Rosaria Chilà, Ezia Bello, et al.
International Journal of Cancer|August 10, 2004
Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinomaSarah Donald, Richard D Verschoyle, Peter Greaves, et al.
Pageof 10